Nurse Practitioner, Family · Southington, CT
NPI
1619499274
Since 2017
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
462 Queen St Ste 303
Southington, CT, 06489
Phone (860) 696-2240
Groups this clinician bills Medicare through
Medicare paid, 2024
$20K
396 services
Medicare patients, 2024
75
Average age 70
Drug cost, 2024
$2.1M
2,884 prescriptions
Company payments, 2025
$942
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michelle L Slavin was code 95251 (test - miscellaneous), 133 times for 61 patients. In total Michelle L Slavin billed 396 services in 9 codes, and Medicare paid $20K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-02-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95251 Test - Miscellaneous | Office | 133 | 61 | $22.52 | $2,996 |
| 99214 Office E&M - Established | Office | 87 | 55 | $88.03 | $7,658 |
| 83036 Blood Count | Office | 75 | 52 | $9.52 | $714 |
| 99215 Office E&M - Established | Office | 64 | 48 | $109.19 | $6,988 |
| 82947 Clinical Chemistry | Office | 24 | 18 | $3.85 | $92.4 |
By year: 2022 $12K for 157 services; 2023 $15K for 266 services; 2024 $20K for 396 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 75 | 52 | $9.52 | $714 |
| 82947 Clinical Chemistry | 24 | 18 | $3.85 | $92.4 |
Medicare prescription drug claims, 2024
In 2024, the drug Michelle L Slavin prescribed most often to Medicare patients was Mounjaro (Tirzepatide), with 352 prescriptions and refills. In total Michelle L Slavin wrote 2,884 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | 352 | 384 | 65 | $414K |
| Ozempic Semaglutide | 183 | 318 | 56 | $297K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 131 | 325 | 57 | $18K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 110 | 298 | 48 | $19K |
| Tresiba Flextouch U-200 Insulin Degludec | 93 | 232 | 33 | $129K |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | 91 | 183 | 28 | $110K |
| Trulicity Dulaglutide | 83 | 119 | 28 | $120K |
| Tresiba Flextouch U-100 Insulin Degludec | 81 | 227 | 35 | $57K |
| Metformin Hcl Er Metformin Hcl | 78 | 207 | 33 | $1,371 |
| Insulin Lispro Kwikpen U-100 Insulin Lispro | 77 | 141 | 27 | $18K |
| Synjardy Xr Empagliflozin/Metformin Hcl | 76 | 188 | 25 | $116K |
| Jardiance Empagliflozin | 75 | 161 | 26 | $97K |
| Lyumjev Kwikpen U-100 Insulin Lispro-Aabc | 72 | 162 | 32 | $67K |
| Metformin Hcl Generic | 67 | 173 | 35 | $380 |
| Glimepiride Generic | 64 | 156 | 20 | $377 |
Brand drugs: 1,943 claims; generic drugs: 641 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michelle L Slavin $942 ($942 in general payments such as food, travel and fees) from 11 companies. The largest payer was Xeris Pharmaceuticals, Inc. with $264.
| Company | Payments | Amount |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 9 | $264 |
| Sequel Med Tech, LLC | 2 | $191 |
| Medtronic, Inc. MDT | 1 | $114 |
| Beta Bionics, Inc. BBNX | 2 | $74.13 |
| Amgen Inc. AMGN | 2 | $61.05 |
| Abbott Laboratories ABT | 3 | $50.17 |
| Novo Nordisk Inc NVO | 2 | $48.8 |
| Mannkind Corporation MNKD | 1 | $44.14 |
| Tandem Diabetes Care, Inc. TNDM | 1 | $41.93 |
| Insulet Corporation PODD | 2 | $29.81 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.